Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer
Conditions: Advanced Non Small Cell Lung Cancer; Uterine Cancer; Soft Tissue Sarcoma Interventions: Drug: PD-1 inhibitor; Drug: Apatinib Sponsors: Hunan Cancer Hospital; Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Hospitals | Non-Small Cell Lung Cancer | Research | Sarcomas | Soft Tissue Sarcoma | Study